This question is particularly relevant given current interest in therapeutic approaches to ADPKD that involve re-expression of PC1 (Dong et al., 2021) or increasing PKD1 and PKD2 protein levels by blocking miR-17 (Lee et al., 2019; Lakhia et al., 2022). The gene discussed is PKD2; the disease is autosomal dominant polycystic kidney disease.